

Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

Children's Hospital Oakland, Oakland, California, United States

St. Louis Children's Hospital, Washington University, St. Louis, Missouri, United States

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States

Hospital de Clinicas de Porto Alegre, Porto Alegre, , Brazil

Children's Hospital, Johannes-Gutenberg Universitaet Mainz, Mainz, , Germany

Addenbrooke's Hospital, Cambridge, England, United Kingdom

Great Ormond Street Hospital for Sick Children, London, England, United Kingdom

Royal Manchester Children's Hospital, Manchester, England, United Kingdom

The purpose of this study is to determine whether the administration of iduronate-2-sulfatase enzyme in a weekly or every other week therapy frequency is safe and efficacious in patients with MPS II.